These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 19895940)

  • 1. High-density lipoprotein and progression rate of atherosclerosis in intravascular ultrasound trials.
    Nicholls SJ
    Am J Cardiol; 2009 Nov; 104(10 Suppl):16E-21E. PubMed ID: 19895940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low high-density lipoprotein cholesterol and increased cardiovascular disease risk: an analysis of statin clinical trials.
    Deedwania P; Singh V; Davidson MH
    Am J Cardiol; 2009 Nov; 104(10 Suppl):3E-9E. PubMed ID: 19895938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The association between resistin, high-density lipoprotein cholesterol and carotid atherosclerosis in elderly women with hypertension.
    Kotani K; Adachi S; Tsuzaki K; Sakane N; Gugliucci A
    Int J Cardiol; 2010 May; 141(2):193-4. PubMed ID: 19108913
    [No Abstract]   [Full Text] [Related]  

  • 4. Atherosclerosis imaging and the future of lipid management.
    Grundy SM
    Circulation; 2004 Dec; 110(23):3509-11. PubMed ID: 15583089
    [No Abstract]   [Full Text] [Related]  

  • 5. Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease?
    Otocka-Kmiecik A; Mikhailidis DP; Nicholls SJ; Davidson M; Rysz J; Banach M
    Prog Lipid Res; 2012 Oct; 51(4):314-24. PubMed ID: 22609245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins.
    Taylor AJ; Sullenberger LE; Lee HJ; Lee JK; Grace KA
    Circulation; 2004 Dec; 110(23):3512-7. PubMed ID: 15537681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of disease: HDL metabolism as a target for novel therapies.
    Rader DJ
    Nat Clin Pract Cardiovasc Med; 2007 Feb; 4(2):102-9. PubMed ID: 17245404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [New trends in lipidology: the increasing role of HDL-cholesterol].
    Paragh G; Harangi M; László M
    Orv Hetil; 2008 Jul; 149(30):1395-404. PubMed ID: 18621598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-density lipoprotein: a fall from grace?
    van Leuven SI; Stroes ES; Kastelein JJ
    Ann Med; 2008; 40(8):584-93. PubMed ID: 18608128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [HDL and CETP in atherogenesis].
    Pöss J; Böhm M; Laufs U
    Dtsch Med Wochenschr; 2010 Feb; 135(5):188-92. PubMed ID: 20082258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis.
    Nicholls SJ; Tuzcu EM; Sipahi I; Grasso AW; Schoenhagen P; Hu T; Wolski K; Crowe T; Desai MY; Hazen SL; Kapadia SR; Nissen SE
    JAMA; 2007 Feb; 297(5):499-508. PubMed ID: 17284700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-density lipoprotein and atheroma monitoring.
    Nicholls SJ; Tuzcu EM
    Curr Opin Cardiol; 2008 Jul; 23(4):386-92. PubMed ID: 18520724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence to support aggressive management of high-density lipoprotein cholesterol: implications of recent imaging trials.
    Taylor AJ
    Am J Cardiol; 2008 Apr; 101(8A):36B-43B. PubMed ID: 18375240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HDL-C: role as a risk modifier.
    Barter P
    Atheroscler Suppl; 2011 Nov; 12(3):267-70. PubMed ID: 22152280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ultrasound imaging techniques for the evaluation of cardiovascular therapies.
    Kastelein JJ; de Groot E
    Eur Heart J; 2008 Apr; 29(7):849-58. PubMed ID: 18334471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation).
    Nicholls SJ; Tuzcu EM; Brennan DM; Tardif JC; Nissen SE
    Circulation; 2008 Dec; 118(24):2506-14. PubMed ID: 19029466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anacetrapib, a cholesteryl ester transfer protein inhibitor.
    Hooper AJ; Burnett JR
    Expert Opin Investig Drugs; 2012 Jan; 21(1):103-9. PubMed ID: 22191425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia.
    Kastelein JJ; van Leuven SI; Burgess L; Evans GW; Kuivenhoven JA; Barter PJ; Revkin JH; Grobbee DE; Riley WA; Shear CL; Duggan WT; Bots ML;
    N Engl J Med; 2007 Apr; 356(16):1620-30. PubMed ID: 17387131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relation of high-density lipoprotein cholesterol:apolipoprotein a-I ratio to progression of coronary atherosclerosis in statin-treated patients.
    Mani P; Uno K; St John J; Tuzcu EM; Nissen SE; Nicholls SJ
    Am J Cardiol; 2014 Sep; 114(5):681-5. PubMed ID: 25030535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increasing high-density lipoprotein cholesterol by cholesteryl ester transfer protein-inhibition: a rocky road and lessons learned? The early demise of the dal-HEART programme.
    Landmesser U; von Eckardstein A; Kastelein J; Deanfield J; Lüscher TF
    Eur Heart J; 2012 Jul; 33(14):1712-5. PubMed ID: 22696435
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.